Qube Research & Technologies (QRT)
ALNY icon

Qube Research & Technologies (QRT)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240M Sell
798,715
-39,472
-5% -$11.9M 0.22% 103
2026
Q1 		$277M Buy
838,187
+63,511
+8% +$21.6M 0.31% 53
2025
Q4 		$308M Sell
774,676
-36,602
-5% -$16.2M 0.31% 46
2025
Q3 		$370M Buy
+811,278
New +$330M 0.38% 34
2025
Q2 		– Sell
-330,347
Closed -$89.2M – 3524
2025
Q1 		$89.2M Sell
330,347
-154,913
-32% -$39.8M 0.1% 249
2024
Q4 		$114M Buy
485,260
+333,098
+219% +$87.6M 0.15% 159
2024
Q3 		$41.8M Buy
+152,162
New +$39.6M 0.06% 396
2024
Q2 		– Sell
-110,759
Closed -$16.6M – 3752
2024
Q1 		$16.6M Buy
110,759
+92,307
+500% +$15.4M 0.03% 638
2023
Q4 		$3.53M Buy
18,452
+17,452
+1,745% +$2.97M 0.01% 1226
2023
Q3 		$177K Buy
+1,000
New +$191K ﹤0.01% 2447
2022
Q4 		– Sell
-1,453
Closed -$291K – 2430
2022
Q3 		$291K Buy
+1,453
New +$277K ﹤0.01% 1634
2022
Q2 		– Sell
-6,951
Closed -$1.14M – 2447
2022
Q1 		$1.14M Buy
6,951
+3,424
+97% +$522K 0.01% 1111
2021
Q4 		$598K Sell
3,527
-41,372
-92% -$7.69M ﹤0.01% 1482
2021
Q3 		$8.48M Buy
+44,899
New +$8.42M 0.11% 240
2020
Q3 		– Sell
-45,459
Closed -$6.73M – 1646
2020
Q2 		$6.73M Buy
+45,459
New +$6.13M 0.1% 261
2020
Q1 		– Sell
-15,545
Closed -$1.79M – 1094
2019
Q4 		$1.79M Buy
+15,545
New +$1.55M 0.06% 389
2018
Q4 		– Sell
-398
Closed -$35K – 314
2018
Q3 		$35K Buy
+398
New +$40K ﹤0.01% 919

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ALNY Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.7% in Q2 2026, selling an estimated $11.9M and leaving 798,715 shares worth $240M. The position accounts for 0.22% of the portfolio, ranked #103.

Qube Research & Technologies (QRT) first reported a position in ALNY in Q3 2018 and has held it in 17 quarters since. The position peaked at $370M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Qube Research & Technologies (QRT) held 798,715 shares of Alnylam Pharmaceuticals worth $240M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 39,472 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $11.9M.
  • Alnylam Pharmaceuticals made up 0.22% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #103 holding.
  • Qube Research & Technologies (QRT) first reported a position in Alnylam Pharmaceuticals in Q3 2018 and has held it in 17 quarters since.
  • Qube Research & Technologies (QRT)'s Alnylam Pharmaceuticals position peaked at $370M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.